Trending...
- City Shares Information on Upcoming Street Closures for Long Beach Marathon - 110
- Solano Home Prices Fall as Sales Rise—Then Mortgage Rates Add a Plot Twist - 102
- California: First Partner Siebel Newsom co-hosts summit elevating social connection as an urgent public health priority at the Vatican
SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing. Other new investors participating in the financing included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel Company), Wellington Management Company, and an undisclosed leading global investment firm. Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corporation, KRX: 14451) and GC (Green Cross Holdings Corporation, KRX: 005250), also participated in the financing. Artiva plans to use the proceeds from the financing to advance its NK cell therapy development programs and expand ongoing research and development activities.
More on The Californer
"The quality and support of the investor groups participating in this financing further validates the promise of our manufacturing first strategy, the potential of our NK cell platform, and our goal to provide safe, effective, and truly off-the-shelf cell therapy treatments that are immediately accessible to cancer patients," said Fred Aslan, M.D., CEO of Artiva. "I would also like to welcome Bong Koh to our board of directors and look forward to drawing upon his expertise as we continue to advance our clinical and other development activities."
"Artiva is a promising company with differentiated technology, strong manufacturing capabilities and a talented management team," said Bong Koh, M.D., with Venrock Healthcare Capital Partners. "I look forward to working closely with Artiva's board and management during this exciting period of growth for the company."
Artiva's cell therapies are designed to leverage the innate anti-tumor biology and safety features of NK cells. The therapies are optimized for targeted anti-cancer activity through CARs, or ADCC enhancement through therapeutic antibody or innate-cell engager combination therapy. Artiva's manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies, and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity.
More on The Californer
About Artiva Biotherapeutics
Artiva's mission is to deliver to cancer patients highly effective cellular immunotherapies that are safe and immediately accessible. Artiva's pipeline includes AB-101, an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers. The company is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. The company's CAR-NK programs include AB-201, a novel HER2-specific CAR-NK cell therapy for the treatment of HER2+ solid tumors, and AB-202, a CD19-specific CAR-NK cell therapy for the treatment of B-cell malignancies, which are being developed under Artiva's master license and option agreement with GC LabCell Corporation, with plans to enter clinical trials in 2022. The company has entered into therapeutic NK cell collaborations and/or license agreements with Merck and with Affimed N.V. Artiva's NK cell platform incorporates cell expansion, activation, and engineering technology developed by the company's corporate partner, GC LabCell, a member of the GC family of companies, one of the Republic of Korea's leading biopharmaceutical groups. Artiva is headquartered in San Diego. For additional information about Artiva Biotherapeutics, please visit www.artivabio.com.
More on The Californer
- City of Long Beach Advises Electrical Vehicle Users About Potential Hazards from Saltwater Exposure
- Artisan Neuromuscular & Sports Massage Therapy Launches Massage Gift Cards in Los Angeles
- WOWX Completes Its Transition from CEX to Decentralized Derivatives Infrastructure
- Free $5,997 AI Program Reveals Blueprint for $1M One-Person Businesses
- City of Long Beach Urges Caution as Coastal Flood and High Surf Warnings Take Effect
"The quality and support of the investor groups participating in this financing further validates the promise of our manufacturing first strategy, the potential of our NK cell platform, and our goal to provide safe, effective, and truly off-the-shelf cell therapy treatments that are immediately accessible to cancer patients," said Fred Aslan, M.D., CEO of Artiva. "I would also like to welcome Bong Koh to our board of directors and look forward to drawing upon his expertise as we continue to advance our clinical and other development activities."
"Artiva is a promising company with differentiated technology, strong manufacturing capabilities and a talented management team," said Bong Koh, M.D., with Venrock Healthcare Capital Partners. "I look forward to working closely with Artiva's board and management during this exciting period of growth for the company."
Artiva's cell therapies are designed to leverage the innate anti-tumor biology and safety features of NK cells. The therapies are optimized for targeted anti-cancer activity through CARs, or ADCC enhancement through therapeutic antibody or innate-cell engager combination therapy. Artiva's manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies, and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity.
More on The Californer
- Voice Actor D.C. Douglas Appears as the Speaker of Books in Disney's "Vampirina: Teenage Vampire"
- California Completes Landmark Transition of Its Accounting Book of Record onto FI$Cal
- Melony "Mellie" Trottier Named Ms. Corporate America Orange County 2027
- Remote Work from Home Jobs - Without College Degree or Experience
- Thursday's Hair Solutions Expands Non-Surgical Hair Replacement for the Transgender Community
About Artiva Biotherapeutics
Artiva's mission is to deliver to cancer patients highly effective cellular immunotherapies that are safe and immediately accessible. Artiva's pipeline includes AB-101, an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers. The company is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. The company's CAR-NK programs include AB-201, a novel HER2-specific CAR-NK cell therapy for the treatment of HER2+ solid tumors, and AB-202, a CD19-specific CAR-NK cell therapy for the treatment of B-cell malignancies, which are being developed under Artiva's master license and option agreement with GC LabCell Corporation, with plans to enter clinical trials in 2022. The company has entered into therapeutic NK cell collaborations and/or license agreements with Merck and with Affimed N.V. Artiva's NK cell platform incorporates cell expansion, activation, and engineering technology developed by the company's corporate partner, GC LabCell, a member of the GC family of companies, one of the Republic of Korea's leading biopharmaceutical groups. Artiva is headquartered in San Diego. For additional information about Artiva Biotherapeutics, please visit www.artivabio.com.
Filed Under: Business
0 Comments
Latest on The Californer
- IMCX 2026 Returns to Downtown Los Angeles October 14-15 With 20+ Creator Economy Speakers
- Roch Dog Publishes a Hotelier's Guide to What Dog Owners Will Actually Pay For
- Oceanside Nonprofit's Free AI Cancer Platform Reaches 87,000 Users in 85 Countries
- City of Long Beach Provides Updates on Ongoing and Planned Peninsula Projects and Coastal Protection Efforts
- Aegean Love Hollywood Premiere on 10/30
- eRacks Founder Recalls the First KVM Forums and Why eRacks Built eVirt on Linux's Own Hypervisor
- PODS Helps Local Residents Make Room for Fall with the Great PODS Fall Refresh Giveaway
- Where to stay for Usher and Chris Brown at SoFi Stadium (November 15 and 16)
- House Junkies Inc. of Visalia Earns BBB Accreditation With A+ Rating
- California: First Partner Siebel Newsom co-hosts summit elevating social connection as an urgent public health priority at the Vatican
- Governor Newsom announces new swiftwater rescue fleet to strengthen California storm preparedness
- Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026
- Agromin and City of Santa Clarita Announce Free Compost Giveaway Program
- Tulsa Air & Space Museum Launches "Give $16 for the F-16" Challenge to Bring Thunderbird Home for Veterans Day
- Hannk And Zubie Join Forces To Shape The Next Generation Of Connected Vehicle Telematics
- Zhengxin Chicken Steak Opens at South Hills Plaza in West Covina
- Coinfiliate Launches Platform to Helps Shoppers Earn Cashback and Creators Earn Referral Rewards
- Russ Lorenson Announces "What I Want For Christmas (20th Anniversary Edition)"
- Best Bracelet Gifts for Her in 2026: Affordable Luxury Jewellery That Looks Expensive
- Holiday Gambling Spending Expected to Rise 12% in December